Early and Polyantigenic CD4 T Cell Responses Correlate with Mild Disease in Acute COVID-19 Donors.
COVID-19
SARS-CoV-2
T cells
acute
breadth
early
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 Jun 2022
28 Jun 2022
Historique:
received:
10
06
2022
revised:
22
06
2022
accepted:
24
06
2022
entrez:
9
7
2022
pubmed:
10
7
2022
medline:
14
7
2022
Statut:
epublish
Résumé
We assessed SARS-CoV-2-specific CD4+ and CD8+ T cell responses in samples from 89 acute COVID-19 patients, utilizing blood samples collected during the first wave of COVID-19 in Italy. The goal of the study was to examine correlations between SARS-CoV-2-specific T cell responses in the early phase comparing mild, moderate, or severe COVID-19 disease outcomes. T cell responses to the spike (S) and non-S proteins were measured in a combined activation-induced marker (AIM) and intracellular cytokine staining (ICS) assay. Early CD4+ T cell responses to SARS-CoV-2 S correlated with milder disease by both AIM and IFNγ ICS readouts. The correlation of S-specific CD4+ T cell responses with milder disease severity was most striking within the first two weeks of symptom onset compared to later time points. Furthermore, donors with milder disease were associated with polyantigenic CD4+ T cell responses that recognized more prominently non-S proteins in addition to S, while severe acute COVID-19 was characterized by lower magnitudes of CD4+ T cell responses and a narrower repertoire. In conclusion, this study highlights that both the magnitude and breadth of early SARS-CoV-2-specific CD4+ T cell responses correlated with milder disease outcomes in acute COVID-19 patients.
Identifiants
pubmed: 35806161
pii: ijms23137155
doi: 10.3390/ijms23137155
pmc: PMC9267033
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : 75N93019C00065
Pays : United States
Références
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Immunity. 2020 Nov 17;53(5):1095-1107.e3
pubmed: 33128877
Front Immunol. 2021 Nov 10;12:748881
pubmed: 34858405
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
Cell Rep. 2021 Feb 9;34(6):108728
pubmed: 33516277
Cell. 2022 Mar 3;185(5):847-859.e11
pubmed: 35139340
Biochem Biophys Res Commun. 2021 Jan 29;538:211-217
pubmed: 33190827
Cell Rep. 2021 Nov 30;37(9):110071
pubmed: 34852222
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
Immunity. 2020 Oct 13;53(4):864-877.e5
pubmed: 32791036
Immunity. 2022 May 10;55(5):738-748
pubmed: 35545026
Nature. 2022 Jan;601(7891):110-117
pubmed: 34758478
J Med Virol. 2021 Sep;93(9):5608-5613
pubmed: 33913544
Sci Immunol. 2020 Jul 17;5(49):
pubmed: 32680954
Nat Rev Immunol. 2022 Jun;22(6):387-397
pubmed: 35484322
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Cell Rep Med. 2021 Jul 20;2(7):100354
pubmed: 34250512
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
Cell Host Microbe. 2022 Mar 9;30(3):388-399.e3
pubmed: 35172129
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Cell Rep Med. 2021 Jun 15;2(6):100312
pubmed: 34056627
Cell. 2022 Jul 7;185(14):2434-2451.e17
pubmed: 35764089
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
Eur J Immunol. 2020 Dec;50(12):1998-2012
pubmed: 33073359
Cell Rep Med. 2021 Feb 16;2(2):100204
pubmed: 33521695
Cell Host Microbe. 2021 Jul 14;29(7):1076-1092
pubmed: 34237248
Semin Immunol. 2021 Jun;55:101505
pubmed: 34711489
Cell Mol Immunol. 2021 Mar;18(3):604-612
pubmed: 33060840
Cell Host Microbe. 2021 Nov 10;29(11):1611-1619.e5
pubmed: 34688376